<i>KRAS</i> mutation status in primary nonsmall cell lung cancer and matched metastases

Abstract

Highly sensitive tools are required to identify biomarkers. The KRAS mutation status mostly was concordant between primary tumors and matched distant metastases. In a few patients, KRAS mutation status differed between different tumor sites.